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Abst rac t
Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. More than 
60% of children with AD are at risk to develop allergic rhinitis or asthma (the atopic march). Patients with AD have 
a unique predisposition to colonization or infection by Staphylococcus aureus. Treatments for AD need to rapidly 
control symptoms of the disease, improve quality of life and prevent exacerbations. Given the chronic and relapsing 
nature of the disease, therapies need to encourage good compliance and be well tolerated.
Key words: atopic dermatitis, treatment, emollients, cosmeceuticals, topical corticosteroids, topical calcineurin 
inhibitors, antihistamines.
Introduction
Atopic dermatitis (AD) is a chronic, recurrent, inflam-
matory cutaneous disease, which may coexist with other 
IgE-dependent atopic diseases such as bronchial asthma, 
allergic rhinitis and food allergy [1, 2]. Atopic dermatitis 
is a result of complex genetic, epigenetic, environmen-
tal and immunological interactions with an overlapping 
epidermal barrier defect [1, 2]. The disease significantly 
reduces the quality of life of patients and their families, 
which leads to serious socioeconomic consequences 
[3–9]. In early childhood, the incidence of the disease is 
similar in both sexes, and only around the age of 6 years 
does the prevalence among girls become higher than in 
boys (3 : 2) [10, 11]. Atopic dermatitis most often begins in 
early childhood. It is believed that 60% of all cases begin 
in the first year of life, and 90% – before the age of 5. The 
disease tends to regress before 5 years of age in 40–80% 
of patients and in 60–90% it subsides before 15 years 
of age [12]. In Poland, the incidence of AD increases in 
large cities, but decreases in rural areas. The prevalence 
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of AD in children ranges from 4.7% to 9.2%, while among 
adults it is from 0.9% to 1.4% [13].
Treatment. General considerations
The fundamentals of AD treatment are based on 
a combination of proper skin care, daily use of emol-
lients and anti-inflammatory treatment, while avoiding 
contact with provocative allergens and irritants [14, 15]. 
Anti-inflammatory therapy should be properly selected 
to include topical corticosteroids (TCSs) and/or topical 
calcineurin inhibitors (TCI) – depending on the disease 
activity (periods of exacerbation and remission, location 
of changes etc.).
Contributing factors
One of the most vital elements of taking medical 
history is identifying potential aggravating factors. Most 
often, in the case of AD, these are airborne allergens, 
foods, climatic factors, stress, hormone levels, cigarettes, 
irritants and microorganisms. Not every patient with AD 
reacts to all of the above-mentioned factors [14, 16]. 
Statistically, 20–40% of young children and infants with 
AD are concurrently diagnosed with a food allergy, most 
commonly to cow’s milk, eggs, fish, peanuts, soya beans 
and wheat [16]. Food allergy and AD often coexist in the 
same patient. Skin lesions occurring in AD, associated 
with food allergy, are more common in patients in the 
developmental age than in adulthood. They are a mani-
festation of the body’s hypersensitivity to certain foods, 
the consumption of which leads to atopic and allergic 
reactions (IgE-mediated, IgE-independent or mixed).
Atopic dermatitis in infants and young children is 
most often associated with an allergy to cow’s milk pro-
tein and egg white, whereas older children, adolescents 
and adults are more commonly allergic to animal and 
airborne allergens.
Clinical studies have shown that in approximately 
50% of the youngest children with AD, exacerbation of 
skin lesions may occur after ingestion of one or more 
harmful ingredients. Adolescents and adults with AD 
also react with exacerbation of lesions after eating cer-
tain foods. Unlike in infancy, hypersensitivity reactions 
to milk protein and egg white (“classical food allergens”) 
are seldom observed in adolescents and adults with AD. 
In this age group, exacerbation of skin lesions more com-
monly is a result of an “allergic cross-reaction” caused by 
simultaneous allergies to pollen and food.
Determination of the etiopathogenic relationship 
between food hypersensitivity and AD is an indication 
for the temporary use of an elimination diet in these pa-
tients [17]. In contrast, airborne allergens (animal dander, 
cockroaches, house dust mites, human skin, molds and 
pollens) are the most common cause of exacerbations in 
older children and adults [18].
First-line therapy: basic treatment 
Primary therapy of AD is based on education, preven-
tion and restoration of the disturbed epidermal barrier 
function by total emollient therapy (Table 1). Emollients 
should be selected on a case-by-case basis depending on 
the degree of skin dryness, diurnal and nocturnal activi-
ties as well as possible contact allergy. The restoration of 
lipids in the damaged epidermal barrier of an AD patient 
can be achieved using the so-called active emollients, 
a mixture of fats that physiologically occur in the stra-
tum corneum. These compounds, such as ceramides, free 
fatty acids and cholesterol, are actively transported using 
specific receptors and ATP to the cytoplasm of the cells in 
the living layers of the epidermis, where they are metab-
olized and then, together with endogenous lipids, they 
form a lipid barrier of the skin. In AD, the best results 
are achieved with active emollients that consist predom-
inantly of ceramides because they are the most deficient 
in this disease [19]. Restoration of the epidermal barri-
er is achieved following each application of emollients, 
but along-lasting improvement of its function takes 2 to 
4 weeks of regular treatment, which is associated with 
the physiological process of differentiation of the epider-
mis, with the final product of the stratum corneum rich 
in lipid membranes.
The crucial part of topical treatment of AD is the use 
of modern emollients that contain agonists of peroxi-
some proliferator-activated receptors (PPARs). These are 
highly unsaturated fatty acids, certain flavonoids, which 
cause activation of specific nuclear receptors and thus 
increase the synthesis of endogenous lipids, improving 
the function of the epidermal barrier; they also have an 
anti-inflammatory effect similar to corticosteroids by 
inhibiting nuclear factor-kB (NF-kB), Th2 cell response, 
mast cells and interleukin 4 [20, 21]. An important objec-
tive of the treatment is to restore proper hydration levels 
of the epidermis. Proper hydration of the stratum corne-
um can be achieved through the use of emollients that, 
in addition to lipids, also contain urea – the main com-
ponent of natural moisturizing factor (NMF), whose role 
is to contain water and glycerol, which is responsible for 
the transport of water from the dermis to the epidermis.
Treatment of AD with a palmitic acid derivative (PEA) 
has been seen to yield good results – PEA is physiolog-
ically present in the epidermis, and in AD its amount is 
drastically reduced. Its topical application stimulates the 
production of endogenous lipids; it has antimicrobial 
properties and also acts on histamine receptors, pre-
venting the degranulation of mast cells [22]. Lubrication 
of dry skin reduces pruritus, hydrates skin and promotes 
the alleviation of inflammation. Regular use of emol-
lients 3–4 times a day reduces the need for TCSs (a ste-
roid-sparing effect) [23, 24]. Atopic skin requires special 
care [15, 24]. The patient’s skin condition is significantly 
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improved by short water baths at 36–37°C, after which 
application of emollients is recommended within 5 min.
Cosmeceuticals
Cosmeceuticals are a separate group of topical prepa-
rations which, due to their high content of active ingredi-
ents, have therapeutic properties or significantly support 
skin care. They are used to rebuild and restore the nor-
mal function of the epidermal barrier and reduce local in-
flammation in AD. The most important active compounds 
used in cosmeceuticals include: vitamins (e.g. vitamins A, 
C, K, niacin), minerals, unsaturated fatty acids, antioxi-
dants (e.g. rutin), plant extracts (e.g. chestnut, ginkgo bi-
loba, arnica), phytoestrogens, b-carotene, active anti-in-
flammatory compounds, fruit acids, cytokines and the 
recently discovered ectoin. Ectoin is capable of limiting 
the inflammatory processes induced by external factors, 
such as ultraviolet radiation. It reduces the extent of DNA 
damage, accelerates cellular repair mechanisms, protects 
Langerhans cells, increases the fluidity of the lipid layer 
and protects against water loss from the epidermis.
The most important role of ectoin is the protection of 
keratinocytes in the epidermis against adverse environ-
mental factors including UV rays, high temperatures and 
dryness [25, 26].
Wet-wrap treatment 
So-called “wet-wrap treatment” (WWT) can be used 
in children aged from 6 months to 10 years with severe 
AD (SCORAD index over 50). The method uses two lay-
ers of dressings: moist dressing, saturated with medica-
ments (emollients or 0.05% fluticasone propionate or 
mometasone furoate at a dilution of 1 : 3 for the body or 
1 : 9 for the face), which is placed directly on the skin, and 
the overlying dry dressing. The therapy lasts 3–14 days 
under close medical supervision, and requires monitor-
ing of morning cortisol levels. A possible side effect may 
be adrenal suppression [27].
Wet dressing has cooling, anti-inflammatory and anti-
pruritic effects. It forms a mechanical barrier against en-
vironmental factors and prevents the child from scratch-
ing, potentially also reducing the amount of TCS used. On 
the other hand, it causes high TCS absorption, increasing 
the risk of bacterial infection of the hair follicles and skin 
atrophy. In addition, this form of therapy requires training 
Table 1. First-line therapy of atopic dermatitis (AD) (based on [15], [24])
Education Explain/demonstrate how to apply emollients
Various topical medications should be used with intervals
In children > 12 months, use shampoos recommended in AD
When talking to the patient (guardian), make sure the recommendations are understood and followed
Revision of recommendations at least once a year
Prevention Avoid allergens and irritants:
Tobacco smoke
Infections
Wool clothing
Stress
Skin 
cleansing
Delicate and precise, mechanical cleansing
Detergents with/without aseptic substances
Suitable galenic forms
pH in the range of 6
Fast bath ≤ 5 min, including 2-min bathing in oil at 27–30°C
Adding 1/2 cup of sodium hypochlorite to the bath eliminates itching
Bath salts – facilitate the removal of exfoliated skin, skin scales, particularly beneficial in severe impetiginization
Emollient 
therapy
Application min. 2–3 times a day!
Glycerol is better tolerated than urea or sodium chloride
Propylene glycol can easily cause irritation in young children < 2 years of age and should not be used in these patients
In children < 2 years of age it is recommended to use emollients without protein allergens and haptens
Do not use emollients containing peanut extracts which increase the risk of sensitization and allergies!
Emollients are poorly tolerated in inflammation sites – use the appropriate doses of emollients (250–500 g/week)
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to be provided to caregivers or patients, which raises its 
cost [28].
A consensus published in 2006 emphasizes that 
WWT is a relatively safe therapy in severe and recurrent 
cases of AD, well tolerated by children and significantly 
improving their quality of life [29]. Spectacularly good 
therapeutic effects can be seen as early as after 1 week 
of treatment; however, in some cases, a significant wors-
ening of AD can develop within 4 weeks after cessation 
of treatment, hence research is being conducted on the 
proactive use of WWT in home care [29]. The results of 
studies encourage the use of this method, yet further 
controlled standardized clinical trials are needed before 
any recommendations can be made [30].
Second-line therapy: mild anti-inflammatory 
treatment
Topical corticosteroids
Topical corticosteroids have been the basis of AD 
treatment for over 50 years. They provide an excellent 
therapeutic effect in combination with emollients. Due 
to dry skin, TCSs are preferred in the form of ointments, 
except in the case of exuding skin lesions, where light-
er forms must be used (lotion, spray, cream). The use 
of TCSs reduces skin colonization by Staphylococcus 
aureus [14]. During exacerbations it is recommended to 
use a TCS of medium potency. Due to the high efficien-
cy obtained in a short time after initiation of treatment 
and their low price, TCSs are often overused. In children, 
these medications should be used very carefully, under 
close dermatological follow-up due to differences in the 
skin structure compared to adults. In Poland, only hy-
drocortisone acetate and hydrocortisone butyrate are 
approved for use in children under 1 year of age, where-
as mometasone furoate, fluticasone propionate and 
methylprednisolone aceponate – characterized by high 
selectivity and affinity to receptors – are approved for use 
in children above 2 years of age. Other TCSs are only ap-
proved for use in patients aged 12 years or older.
Side effects of corticosteroids
Long-term use of TCSs, particularly those from high 
potency groups, is associated with common side effects: 
skin atrophy, permanent telangiectasia, stretch marks, 
hypertrichosis, depigmentation, perioral dermatitis, acne 
rosacea, bacterial and/or fungal infections and withdraw-
al effects (exacerbation of skin lesions after discontin-
uation of the drug), as well as tachyphylaxis (gradual 
decrease in efficacy with prolonged treatment). Local 
application of strong TCSs on large surfaces in children, 
especially infants, can cause undesirable systemic symp-
toms: inhibition of the hypothalamic-pituitary-adrenal 
axis, growth retardation and osteoporosis. Fear of side 
effects (as well as the increasingly common steroid pho-
bia) is a common cause of poor compliance with doctor’s 
recommendations by patients or, in the case of children, 
by parents, which results in a lack of treatment efficacy. 
To avoid potential side effects, it is recommended to use 
the so-called intermittent therapy, involving the use of 
TCSs only 2–3 days per week, alternating with emollients. 
Topical corticosteroids should be used according to the 
manufacturer’s recommendations, once a day, as their 
more frequent use does not increase treatment efficacy 
but increases the risk of side effects [14, 18, 24, 31–33].
“Steroid phobia” (“corticophobia”)
More than half of AD patients are afraid to use TCSs, 
as revealed by studies on steroid phobia among these pa-
tients. In addition, it has been shown that patients have 
little knowledge of the therapeutic potential of TCSs and 
their adverse effects, and the main source of information 
about TCSs for patients is doctors and pharmacists. The 
problem of steroid phobia is not limited to Poland but 
is widespread in Europe and results in ineffectiveness 
of local AD therapy. It seems that the effectiveness of 
AD treatment could be improved by proper education of 
patients and personal interaction fostering mutual trust 
between patients and healthcare professionals [34].
Topical calcineurin inhibitors 
Topical calcineurin inhibitors, tacrolimus and pimecro-
limus, inhibit T cell activation and the release of inflam-
matory cytokines. Pimecrolimus in the form of 1% cream 
is recommended as first-line therapy in mild AD, and its 
clinical profile suggests that it may be considered as the 
treatment of choice for mild to moderate AD, in both 
children and adults, especially in sensitive areas of the 
skin [35]. Tacrolimus 0.03% and 0.1% ointment is recom-
mended in moderate to severe atopic eczema. Compared 
to pimecrolimus, tacrolimus has a faster and more potent 
action, and clinical improvement after its application is 
visible already in the first week of treatment. These med-
ications are administered twice daily until resolution of 
inflammation. They can be safely used for many months 
on all areas of the skin, including sensitive ones such as 
the eyelids, face, neck, and intertriginous areas, as well 
as the genitals in both adults and children. In contrast 
to TCSs, TCIs do not inhibit the synthesis of collagen, do 
not cause epidermal thinning or vasodilation, nor do they 
damage the skin barrier. The most common adverse re-
actions associated with the use of TCIs are burning and 
redness of the skin at the site of application, which dis-
appears after a few days [14, 35, 36].
Based on analysis of existing results of the treatment, 
it is believed that the restrictions on the use of pimecroli-
mus in infants are unjustified. It is suggested to develop 
new recommendations and warnings in the labelling of 
topical calcineurin inhibitors [37].
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Proactive (maintenance) therapy
Proactive therapy is based on the use of tacrolimus 
ointment twice a week for up to 12 months after the dis-
appearance of skin lesions. For patients with relapsing 
AD, pimecrolimus cream should be applied as mainte-
nance therapy to the previously affected skin following 
complete resolution of lesions, either once daily for 
7 days a week for up to 3 months or less frequently, de-
pending on the advice of the treating physician [37]. Re-
duction of exacerbations of AD, increased patient com-
pliance, improved quality of life of patients and reduced 
cost of treatment of AD have been observed among pa-
tients using the proactive therapy [38, 39].
Antimicrobial therapy
Each exacerbation of AD can be associated with bac-
terial infection; staphylococcal infections are the most 
common. The skin of patients with AD is colonized with 
this pathogen in 90% of cases. An attempt was made to 
prove that eradication of Staphylococcus aureus signifi-
cantly reduces the severity of the disease [40]; howev-
er, due to increasing drug resistance and the defective 
antimicrobial peptide profile in AD, sustained decoloni-
zation of the skin is practically impossible [41]. Studies 
indicate the efficacy of octenidine, chlorhexidine, mupi-
rocin, fusidic acid and retapamulin [40, 42, 43]. Due to 
the above-mentioned antibiotic resistance, chronic use 
of topical antibiotics is not recommended. The rationale 
for the use of oral antibiotics is exacerbation of AD with 
clinical signs of bacterial infection [44–46]; in other cas-
es, treatment with oral antibiotics is not recommended 
[14, 47]. It is important to note that anti-inflammatory 
treatment alone (TCIs, TCSs, UV) reduces Staphylococcus 
aureus colonization in AD [14, 42]. Skin infection caused 
by herpes simplex virus (HSV) is often manifested as 
Kaposi varicelliform eruption that requires systemic an-
tiviral therapy [48]. Ketoconazole and ciclopiroxolamine 
are proposed for the treatment of superficial infections 
caused by Malassezia sympodialis [49–51].
Tannins
Tannins have played an important role in dermatol-
ogy for many years. Because of their astringent, anti-in-
flammatory, antipruritic, antimicrobial and desiccant 
properties, they are widely used in the treatment of in-
flammatory and exudative skin diseases such as AD. Lack 
of absorption after application, leading to absence of 
systemic effects, allows tannins to be used with no age 
limits in infants, children, the elderly, as well as in preg-
nant women. Tannins can be used regularly and there 
have been no reported interactions during simultaneous 
application with other medicinal products [52]. It comes 
in three forms: lotions, creams and a solution for baths 
and wraps. In situations where there is minimal exudate, 
dryness and peeling, the use of tannins in the form of 
creams is preferred. The mechanism of action of tannins 
and emollient cream base make this formulation effective 
in inflammatory skin diseases with skin dryness, either 
alone in mild forms of AD, or in combination with local 
corticosteroids, antifungals and antibiotics in more se-
vere cases complicated with secondary infection [53]. The 
lotion form of tannins additionally contains zinc oxide 
and talc, which exhibit hygroscopic properties, making 
it favorable for use as monotherapy or adjunctive thera-
py of skin lesions accompanied by exudate and located 
in the vicinity of intertriginous areas. Synthetic tannins 
are available in the form of solutions recommended for 
partial and whole body baths, washing and wraps [54].
Antihistamines 
First-generation antihistamines (AH1), among which 
only hydroxyzine is currently recommended, can inhibit 
histamine activity in the subcortical centers of the cen-
tral nervous system (CNS), exerting an antipruritic and 
sedative effect, which is advantageous in the case of AD 
patients who experience sleep disorders and difficulties 
in falling asleep. Antihistaminic activity may accelerate 
the repair of the damaged epidermal barrier [55, 56]. 
Gschwandtner et al. demonstrated that the addition of 
histamine to keratinocyte cultures (in vitro) resulted in 
a significant decrease in the expression of keratin 1/10, 
filaggrin and loricrin [55]. Second-generation antihista-
mines (AH2) are particularly useful in patients with AD 
accompanied by conjunctivitis or allergic rhinitis [15]. 
Higher specificity of binding to histamine H1 receptor, 
longer half-life and hydrophilic structure of AH2 contrib-
ute to improved efficacy and safety of these drugs [57].
The safety of cetirizine and levocetirizine has been 
confirmed in two large studies: ETAC and EPAAC, in 
which AD children aged 1 to 3 years received treatment 
for 18 months [57, 58]. ETAC (Early Treatment of the Atop-
ic Child) was the first prospective study evaluating the 
safety and efficacy of cetirizine in the pediatric popula-
tion. Serious adverse events were rare and more com-
mon in the placebo group. It has been shown that the 
use of cetirizine for a period of 18 months in 1- to 2-year-
old children with AD reduced their risk of asthma by half 
[58]. The EPAAC study involved a group of 510 children 
with AD between 12 and 24 months of age. No significant 
adverse effects were observed, except for upper respira-
tory tract infections, gastrointestinal disorders and exac-
erbation of allergic diseases. There were no statistically 
significant differences in the incidence of these adverse 
events between the groups receiving levocetirizine and 
placebo [59].
Bilastine and rupatadine are new antihistamines, 
approved only for the treatment of allergic rhinitis and 
urticaria. Rupatadine can be used from 6 years of age, 
and bilastine from 12 years of age (Table 2). Bilastine has 
a moderate affinity and high selectivity to H1 receptors 
[60]. After absorption, it is not metabolized and is excret-
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ed with the urine. It has no effect on cardiac arrhythmia 
even with concomitant administration of ketoconazole. 
Therapeutic doses of bilastine have no effects on psycho-
motor functions [60]. Data on antipruritic efficacy of first- 
and second-generation antihistamines in AD are limited 
and there is insufficient evidence for the widespread use 
of these drugs in the treatment of pruritus in AD [24].
Third-line therapy: systemic treatment 
In AD patients in whom local therapy fails to improve 
the skin condition, the following medications can be 
considered: cyclosporine A, methotrexate, azathioprine, 
mycophenolate mofetil, systemic corticosteroids and 
phototherapy [14, 15, 31, 54].
Cyclosporine A (CsA) is recommended as the first-
line therapy in severe cases of chronic AD in adults. In 
children and adolescents, its use should be considered 
only in severe cases of AD. Recommendations for use in 
children are based on the results of individual cohorts 
and individual randomized controlled studies (“off-label” 
indications) [24, 60, 61]. Cyclosporine A reduces inflam-
mation, the size of lesions, the severity of pruritus, and 
improves the quality of sleep. The recommended start-
ing dose is 2.5–3.5 mg/kg b.w./day in two divided doses 
and shouldnot exceed 5 mg/kg b.w./day [61]. After ob-
taining improvement of skin lesions, it is recommended 
to reduce the CsA dose by 0.5–1.0 mg/kg b.w./day every 
2 weeks [62]. The desired effects of CsA treatment, name-
ly decreased pruritus and inflammation of the skin, can 
be seen as early as 2–6 weeks after the initiation of the 
therapy [60, 62]. Withdrawal of the drug is associated 
with a risk of recurrence of skin lesions within several 
weeks after discontinuation of treatment; it is estimat-
ed, however, that after the treatment the skin condition 
does not return to the pre-CsA treatment state [61, 62].
The drug can be administered in continuous long-term 
therapy; however, administration in cycles lasting on av-
erage 12 weeks is recommended. It has been shown that 
CsA at a dose of 2.5–5.0 mg/kg/day given in cycles (cycle 
duration of 12–16 weeks) quickly leads to a significant 
improvement or disappearance of lesions in 80–90% of 
patients [24]. Despite the unquestionable efficacy of CsA 
in the treatment of AD, the use of this drug carries the 
risk of serious side effects. Most side effects that appear 
during the therapy resolve after discontinuation of the 
drug. In order to prevent or reduce the risk of their occur-
rence, strict monitoring of treatment is recommended. 
Patients receiving this drug should be regularly exam-
ined for blood pressure and renal parameters. The risk of 
nephrotoxicity increases when the dose exceeds 5 mg/
kg b.w./day, when there are persistent elevated creati-
nine values, as well as in the elderly. Permanent kidney 
damage (tubular disorders, vasculopathy) can occur in 
patients receiving CsA continuously over a period of more 
than 2 years [62]. In short-term and intermittent CsA 
treatment, renal dysfunction is usually transient. In chil-
dren, the risk of renal toxicity is lower than in adults. Un-
common side effects during treatment with CsA include 
neurological symptoms such as headaches, convulsions, 
paresthesia, as well as gastrointestinal disorders, infec-
tions, gingival hyperplasia, hirsutism, hyperlipidemia, 
electrolyte disturbances, increased risk of developing skin 
cancers and lymphoproliferative disorders. The monitor-
ing of blood CsA concentrations during treatment is not 
required, since CsA levels are only marginally correlated 
with its efficacy and toxicity [63]. Despite the lack of clin-
ical evidence, discontinuation of CsA 2 weeks before the 
scheduled vaccination and re-introduction of the drug 
4 to 6 weeks later is recommended [15].
Methotrexate (MTX), azathioprine (AZA) and myco-
phenolate mofetil (MMF) can be used off-label in adult 
patients with AD, when CsA is ineffective or there are 
contraindications to its use. There are not enough ran-
domized, double-blind, placebo-controlled, prospective 
clinical studies evaluating the treatment with AZA, MTX 
or MMF in children and adolescents with AD [15].
Methotrexate is indicated for the treatment of severe 
AD that is resistant to other treatments. It has been em-
phasized that it is the second most common drug used in 
the treatment of severe AD after CsA. There are a number 
of literature reports on the safety and efficacy of MTX 
in AD. These reports mainly involve adult patients [64]. 
There are also isolated reports on the efficacy and safety 
of MTX in children [65]. Currently, MTX is recommend-
ed for the treatment of AD in adults at doses similar as 
in the treatment of psoriasis, i.e. 10–20 mg/week. It can 
be used in a single dose once a week, but it is more of-
ten applied in three doses of 2.5–7.5 mg every 12 h once 
a week [66]. Other authors recommend the use of MTX at 
doses of 7.5–25 mg/week for adults and 0.2–0.7 mg/kg/
week in children [63]. The treatment is usually well toler-
ated, but there is potential for serious adverse reactions. 
It is believed that the incidence and severity of adverse 
events are dose related. Adverse reactions reported were 
mostly due to high doses of MTX used as chemother-
Table 2. Approved ages for using certain antihistamines
Antihistamines Age
Fenistil 2 months
Hydroxyzine 12 months
Cetirizine 2 years 
Levocetirizine 2 years 
Loratadine 2 years 
Desloratadine 1 year 
Fexofenadine 12 years 
Bilastine 12 years 
Rupatadine 6 years 
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apy. More common side effects include hepatotoxicity, 
bone marrow suppression, pulmonary fibrosis and renal 
failure. In addition, reduced resistance to infection, leu-
kopenia, anorexia, dizziness, headache, abdominal pain, 
ulcerative stomatitis, inflammation and ulceration of the 
bowel are frequently observed [67].
Azathioprine has been used off-label in the treatment 
of skin conditions including severe AD resistant to oth-
er treatments. The exact mechanism of action of AZA in 
AD is not yet fully understood. In vitro studies suggest 
that AZA has a suppressive and toxic effect on Langer-
hans cells [68]. It is noted that AZA is very effective in 
the treatment of AD, but due to its mechanism of action, 
the therapeutic effect of the drug may be delayed [69]. 
In some patients the full therapeutic effect is achieved 
after 12 weeks or even later. It is recommended to use 
AZA at doses of 1–3 mg/kg b.w./day. Before starting the 
treatment, the activity of thiopurine methyltransferase 
(TPMT), an enzyme involved in the metabolism of 6-mer-
captopurine, should be assessed, because people with 
an inherited deficiency of this enzyme have an increased 
risk of myelosuppression. TPMT gene mutations may 
affect the efficacy and safety of treatment with AZA. 
Determination of TPMT levels allows for adjustment of 
individual doses and reduces the risk of bone marrow 
damage [70–73].
Due to the fact that AD is common in children, the 
question arises whether AZA is useful in treating this 
disease in children. Some authors have used the drug in 
severe cases of AD in children and reported its efficacy. 
No toxic effects on the bone marrow have been observed 
[74, 75]. It has also been shown that AZA not only im-
proves the clinical picture but also lowers total serum IgE 
levels in children and adolescents with AD [76].
Azathioprine has a number of side effects. The most 
common ones include bone marrow failure and immune 
system disorders. Vascular disorders (vasculitis), gastro-
intestinal disorders (nausea, vomiting), and liver disor-
ders have also been reported. Therefore, it is necessary 
to monitor transaminases and blood cell counts during 
treatment. According to the summary of Product Char-
acteristics, blood cell counts should be monitored once 
a week during the first 8 weeks of therapy. At later stag-
es of treatment, the frequency of blood cell count tests 
should be reduced to once per month, then once every 
3 months. In the case of decreased levels of leukocyte or 
platelet counts, or if there are other side effects, the dose 
should be reduced. When using AZA, patients should not 
be vaccinated with vaccines containing live microorgan-
isms. Reaction to vaccines containing killed microorgan-
isms can also be weakened. Due to the teratogenic ef-
fects of AZA, it should not be used during pregnancy and 
breastfeeding [69].
Systemic corticosteroids (CS) are approved for the 
treatment of AD, mainly in adult patients for up to 
1 week, in carefully selected cases of disease exacerba-
tion [15].
In everyday practice (unlike the published results of 
clinical trials), the most common causes of discontinu-
ation of treatment with CS include: side effects, lack of 
effectiveness of treatment, patient non-compliance and 
treatment discontinuation after clinical improvement. 
In a 10-year observational study involving Dutch AD pa-
tients, treatment with oral glucocorticosteroids, MMF, 
and CsA was associated with the lowest frequency of 
side effects (5%, 22% and 24%, respectively). More side 
effects, mainly gastrointestinal, were seen after treat-
ment with AZA (38%) and MTX (41%). Furthermore, lack 
of effectiveness of therapy was the cause in 15% for CsA 
and AZA, 20% for CS, 44% for MMF and 65% for MTX [77].
Probiotics have been studied as a potential treat-
ment of AD. The rationale for the application of probiot-
ics is that bacteria induce Th1 rather than Th2 immune 
responses, which may reduce the production of IgE 
antibodies. Some authors reported limited benefits of 
probiotics in the prevention and treatment of AD. These 
studies need to be confirmed [78].
Phototherapy
All types of phototherapy are effective in AD: natural 
light, narrow-band UVB (NB-UVB, 311 nm), broad-band 
UVB (BB-UVB, 290–320 nm), UVA (320–400 nm), UVA 
with psoralens (5-methoxypsoralen, 8-methoxypsoralen 
– photosensitizing compounds taken orally 1 or 2 h prior 
to irradiation) used orally or topically (PUVA), UVA and 
UVB (UVAB), and UVA1 (340–400 nm). There is no evi-
dence for the superiority of one method over another 
due to the scarcity of comparative studies. All we know 
is that natural sunlight is the least effective compared to 
artificial light sources. The most commonly used method 
is UVB phototherapy [63].
Therapeutic protocols differ depending on the region 
of the world and local recommendations. In the case of 
broad-spectrum UVB, a skin phototype-based radiation 
dosage protocol can be used. The starting doses for each 
phototype are: I: 20 mJ/cm2; II: 25 mJ/cm2; III: 30 mJ/cm2; 
IV: 40 mJ/cm2; V: 50 mJ/cm2; VI: 60 mJ/cm2. At each sub-
sequent irradiation, the doses should be increased by 
a specific value depending on the phototype: I: 5 mJ/cm2; 
II: 10 mJ/cm2; III: 15 mJ/cm2; IV: 20 mJ/cm2; V: 25 mJ/cm2; 
VI: 30 mJ/cm2. The subsequent doses should be admin-
istered 3–5 times per week [63].
Depending on the minimal erythema dose (MED), the 
starting dose of BB-UVB should be equal to 50% of MED, 
in the next 10 treatments the starting dose should be 
increased by 25%, in treatments 11–20, the dose should 
be further increased by 10%, and in the subsequent 
treatments the dose is at the discretion of the attend-
ing physician. If the patient misses a treatment session, 
the following rules apply: 1. when 1 week is missed, the 
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last dose can be repeated; 2. when 2 weeks are missed, 
the dose should be reduced by 50%; 3. when 3 weeks 
are missed, the dose should be reduced by 75%; 4. when 
4 weeks are missed, phototherapy should start from the 
beginning.
Skin phototype-based dosing regimens can also 
be used in the case of narrow-range UVB. The starting 
doses for each phototype are: I: 130 mJ/cm2; II: 220 mJ/
cm2; III: 260 mJ/cm2; IV: 330 mJ/cm2; V: 350 mJ/cm2; 
VI: 400 mJ/cm2. With each subsequent treatment, the 
dose should be increased by a value depending on the 
phototype: I: 15 mJ/cm2 (maximum dose 2000 mJ/cm2); 
II: 25 mJ/cm2 (maximum dose 2000 mJ/cm2); III: 40 mJ/
cm2 (maximum dose 3000 mJ/cm2); IV: 45 mJ/cm2 (maxi-
mum dose 3000 mJ/cm2); V: 60 mJ/cm2 (maximum dose 
5000 mJ/cm2); VI: 65 mJ/cm2 (maximum dose 5000 mJ/
cm2). The subsequent doses should be administered 3–5 
times a week [63].
In contrast, the MED-based dosage is as follows: 
starting dose as in BB-UVB: 50% of MED, in the first 
20 treatments, the dose should be increased by 10%, the 
following treatments – at the discretion of the physician. 
If the patient misses a treatment session, the follow-
ing rules apply: 1. when 1 week is missed, the last dose 
can be repeated; 2. when 2 weeks are missed, the dose 
should be reduced by 25%; 3. when 3 weeks are missed, 
the dose should be reduced by 50%; 4. when 4 weeks are 
missed, phototherapy should start from the beginning.
Maintenance therapy by NB-UVB: when regression 
of more than 95% is obtained: 1 treatment per week for 
4 weeks – same as the last dose, followed by reduction 
in the dose by 25% every 2 weeks – for 4 weeks, then 
once a month a dose equal to 50% of the highest dose 
[63]. PUVA photochemotherapy must also be conduct-
ed according to phototype: starting dose in phototype 
I: 0.5 J/cm2; II: 1.0 J/cm2; III: 1.5 J/cm2; IV: 2.0 J/cm2; 
V: 2.0 J/cm2; VI: 3.0 J/cm2. In each subsequent treat- 
ment, the dose should be increased by 0.5 J/cm2 in 
skin phototypes I and II (maximum dose 8 J/cm2), 1.0 J/
cm2 in phototypes III and IV (maximum dose 12 J/cm2), 
and 1.5 J/cm2 in phototypes V and VI (maximum dose 
20 J/cm2) [63].
Phototherapy can be used either alone or in combina-
tion with emollients or TCS. Calcineurin inhibitors should 
be used with caution during phototherapy because of 
the manufacturer’s warnings. It is believed that side ef-
fects of phototherapy are uncommon. Their frequency is 
different depending on the method. Side effects include 
redness and tenderness after irradiation, itching, burns 
and solar skin damage. Less common adverse events in-
clude skin cancers, melanoma (mainly with PUVA), lenti-
go, photosensitivity reactions (mainly polymorphic light 
eruptions), folliculitis, photo-onycholysis, reactivation of 
HSV, excessive facial hair, cataract (also with PUVA). Pa-
tients who use psoralens complain of nausea, vomiting 
and headaches [63, 79, 80].
In the case of phototherapy and photochemotherapy 
for children, NB-UVB is recommended as the treatment 
of choice for patients who have not responded to topical 
therapy [15, 24]. Cases of skin cancers have been report-
ed in patients who received PUVA treatment as children; 
for this reason, this is not a first-choice method in the 
treatment of AD [63].
Specific immunotherapy
Specific allergen immunotherapy (AIT) is the only 
method of causal treatment of AD. Allergen immu-
notherapy is indicated in patients with AD in cases of 
inadequate response to previous treatment with docu-
mented IgE-mediated allergy to airborne allergens [15, 
81–83]. Based on literature and our own experience we 
can conclude that AIT in AD has a high clinical efficacy 
in the treatment of patients with symptoms of allergy 
to perennial and seasonal aeroallergens, particularly 
those who are allergic to one group of allergens [15, 84]. 
To date, the clinical effects of using AIT have been best 
documented for patients allergic to house dust mites and 
pollen [84, 85]. There are no contraindications for desen-
sitization of AD patients with other coexisting AD like 
allergic rhinitis or mild asthma [15, 83]. The effectiveness 
of AIT depends on the correct classification of patients, 
proper selection of the composition of the vaccine and 
its proper handling. The composition of vaccines should 
be based on the results of a thorough medical history, 
physical examination, and detailed allergological diagno-
sis based, among others, on skin prick tests and assess-
ments of specific IgE in serum. The correct composition 
of the vaccines and the order of their administration in 
AD patients with polyvalent allergy determines the suc-
cess of AIT. When planning AIT in patients with AD, aller-
gic diagnosis should not be limited to skin prick tests but 
should be supplemented with assessment of the level of 
specific IgE to the respective allergens [84, 85]. Side ef-
fects tend to occur mainly during the induction phase of 
AIT and are usually mild and transient. Most often they 
appear in the form of erythema and swelling of the skin 
at the site of vaccination. General reactions are less com-
mon and occur as focal reactions distant from the site of 
administration of the allergen, or as general symptoms. 
Exacerbation of rhinitis or asthma has been reported, as 
well as pruritus and urticaria. Less frequently reported 
non-specific symptoms included increased temperature, 
headache, dizziness, weakness, and muscle fatigue. In 
individual cases, hypotension, laryngeal edema and even 
anaphylactic shock can occur. Usually, side effects of AIT 
are mild and transient and relate primarily to skin symp-
toms. However, when using AIT, one must always be pre-
pared for pharmacological and anesthesiological inter-
ventions [85]. Allergen immunotherapy should be carried 
out systematically for at least 4–5 years, by a specialist 
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doctor, in a safe environment, with due consideration of 
the possibility of adverse reactions [84, 85].
Alternative treatments
There is insufficient evidence of the efficacy of oral 
or local use of unsaturated fatty acids, as well as starch 
and brine baths. There is also insufficient evidence to 
support the use of Chinese herbs in the treatment of AD. 
There is no evidence of the effectiveness of AD treatment 
using methods such as acupuncture, homeopathy, and 
aromatherapy [15]. It seems that supplementation with 
vitamins D or E may be useful in the treatment of AD, but 
this requires further controlled studies before any specif-
ic recommendations can be made [15].
Conclusions
The treatment of AD should be based on experience 
and close cooperation with the patient and/or parents, 
education, avoidance of aggravating factors of the dis-
ease, restoration of disturbed functions of the skin 
barrier, reduction of itching and elimination of skin in-
flammation and infection. Patients require frequent der-
matological consultations, and in the case of generalized 
erythrodermic changes hospitalization may be necessary.
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